Literature DB >> 20651075

Prostate cancer susceptibility variants confer increased risk of disease progression.

Iona Cheng1, Sarah J Plummer, Christine Neslund-Dudas, Eric A Klein, Graham Casey, Benjamin A Rybicki, John S Witte.   

Abstract

BACKGROUND: Genome-wide association studies have identified numerous single nucleotide polymorphisms (SNP) associated with the risk of prostate cancer. Our objective was to determine whether these SNPs affect the progression of prostate cancer.
METHODS: We genotyped 26 SNPs previously associated with prostate cancer risk among 788 aggressive prostate cancer patients who were treated by radical prostatectomy or radiation therapy. Prostate cancer progression was defined as biochemical recurrence based on posttreatment prostate-specific antigen levels of >0.3 ng/mL for radical prostatectomy patients or a 2-ng/mL increase above the nadir for radiation therapy patients, initiation of hormone treatment, or metastases. We assessed the association between independent and combined SNPs and disease progression by Cox proportional hazards regression.
RESULTS: Five SNPs showed independent associations with prostate cancer progression (rs12621278, rs629242, rs9364554, rs4430796, and rs5945572) based on stepwise regression analysis. The strongest SNP was rs12621278 in the ITGA6 locus, which was associated with a 2.4-fold increased risk of progression (P = 0.0003). When considering the sum of risk alleles across these five SNPs, each additional allele was associated with a 29% increase in risk of progression (95% confidence interval, 1.12-1-47).
CONCLUSIONS: We found that five of the recently highlighted prostate cancer susceptibility loci also influence prostate cancer progression beyond the known clinicopathologic predictors. If confirmed, these genetic variants might help clarify which tumors are likely to progress and require more aggressive treatment in contrast to those that might not have substantial effects on morbidity or mortality. IMPACT: Genetic susceptibility variants for prostate cancer development may also inform disease progression. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651075      PMCID: PMC2950095          DOI: 10.1158/1055-9965.EPI-10-0268

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  36 in total

1.  Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.

Authors:  Michael O Ports; Ray B Nagle; Gerald D Pond; Anne E Cress
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

2.  Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Thorarinn Blondal; Arnaldur Gylfason; Bjarni A Agnarsson; Kristrun R Benediktsdottir; Droplaug N Magnusdottir; Gudbjorg Orlygsdottir; Margret Jakobsdottir; Simon N Stacey; Asgeir Sigurdsson; Tiina Wahlfors; Teuvo Tammela; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Berta Saez; Javier Godino; Sebastian Navarrete; Fernando Fuertes; Laura Murillo; Eduardo Polo; Katja K Aben; Inge M van Oort; Brian K Suarez; Brian T Helfand; Donghui Kan; Carlo Zanon; Michael L Frigge; Kristleifur Kristjansson; Jeffrey R Gulcher; Gudmundur V Einarsson; Eirikur Jonsson; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Jeffrey R Smith; Johanna Schleutker; Rosa B Barkardottir; Augustine Kong; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2009-09-20       Impact factor: 38.330

3.  Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Authors:  Rosalind A Eeles; Zsofia Kote-Jarai; Ali Amin Al Olama; Graham G Giles; Michelle Guy; Gianluca Severi; Kenneth Muir; John L Hopper; Brian E Henderson; Christopher A Haiman; Johanna Schleutker; Freddie C Hamdy; David E Neal; Jenny L Donovan; Janet L Stanford; Elaine A Ostrander; Sue A Ingles; Esther M John; Stephen N Thibodeau; Daniel Schaid; Jong Y Park; Amanda Spurdle; Judith Clements; Joanne L Dickinson; Christiane Maier; Walther Vogel; Thilo Dörk; Timothy R Rebbeck; Kathleen A Cooney; Lisa Cannon-Albright; Pierre O Chappuis; Pierre Hutter; Maurice Zeegers; Radka Kaneva; Hong-Wei Zhang; Yong-Jie Lu; William D Foulkes; Dallas R English; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Jonathan Morrison; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Rosemary A Wilkinson; Edward J Saunders; Elizabeth C Page; Emma J Sawyer; Stephen M Edwards; David P Dearnaley; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Nicholas Van As; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Colin S Cooper; Melissa C Southey; Artitaya Lophatananon; Jo-Fen Liu; Laurence N Kolonel; Loic Le Marchand; Tiina Wahlfors; Teuvo L Tammela; Anssi Auvinen; Sarah J Lewis; Angela Cox; Liesel M FitzGerald; Joseph S Koopmeiners; Danielle M Karyadi; Erika M Kwon; Mariana C Stern; Roman Corral; Amit D Joshi; Ahva Shahabi; Shannon K McDonnell; Thomas A Sellers; Julio Pow-Sang; Suzanne Chambers; Joanne Aitken; R A Frank Gardiner; Jyotsna Batra; Mary Anne Kedda; Felicity Lose; Andrea Polanowski; Briony Patterson; Jürgen Serth; Andreas Meyer; Manuel Luedeke; Klara Stefflova; Anna M Ray; Ethan M Lange; Jim Farnham; Humera Khan; Chavdar Slavov; Atanaska Mitkova; Guangwen Cao; Douglas F Easton
Journal:  Nat Genet       Date:  2009-09-20       Impact factor: 38.330

4.  Established prostate cancer susceptibility variants are not associated with disease outcome.

Authors:  Fredrik E Wiklund; Hans-Olov Adami; Sigun L Zheng; Pär Stattin; William B Isaacs; Henrik Grönberg; Jianfeng Xu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

5.  Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.

Authors:  Jianfeng Xu; Sarah D Isaacs; Jielin Sun; Ge Li; Kathleen E Wiley; Yi Zhu; Fang-Chi Hsu; Fredrik Wiklund; Aubrey R Turner; Tamara S Adams; Wennuan Liu; Bruce J Trock; Alan W Partin; Baoli Chang; Patrick C Walsh; Henrik Grönberg; William Isaacs; Siqun Zheng
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

Review 6.  Prostate cancer genomics: towards a new understanding.

Authors:  John S Witte
Journal:  Nat Rev Genet       Date:  2008-12-23       Impact factor: 53.242

7.  Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.

Authors:  A Karim Kader; Jielin Sun; Sarah D Isaacs; Kathleen E Wiley; Guifang Yan; Seong-Tae Kim; Helen Fedor; Angelo M DeMarzo; Jonathan I Epstein; Patrick C Walsh; Alan W Partin; Bruce Trock; S Lilly Zheng; Jianfeng Xu; William Isaacs
Journal:  Prostate       Date:  2009-08-01       Impact factor: 4.104

8.  Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease.

Authors:  Liesel M FitzGerald; Briony Patterson; Russell Thomson; Andrea Polanowski; Stephen Quinn; Jesper Brohede; Timothy Thornton; David Challis; David A Mackey; Terence Dwyer; Simon Foote; Garry N Hannan; James Stankovich; James D McKay; Joanne L Dickinson
Journal:  Eur J Hum Genet       Date:  2008-10-01       Impact factor: 4.246

9.  Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.

Authors:  Kathryn L Penney; Claudia A Salinas; Mark Pomerantz; Fredrick R Schumacher; Christine A Beckwith; Gwo-Shu Lee; William K Oh; Oliver Sartor; Elaine A Ostrander; Tobias Kurth; Jing Ma; Lorelei Mucci; Janet L Stanford; Philip W Kantoff; David J Hunter; Meir J Stampfer; Matthew L Freedman
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

10.  The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.

Authors:  Tamara E King; Sangita C Pawar; Lisa Majuta; Isis C Sroka; Danyel Wynn; Manolis C Demetriou; Raymond B Nagle; Frank Porreca; Anne E Cress
Journal:  PLoS One       Date:  2008-10-28       Impact factor: 3.240

View more
  19 in total

1.  Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.

Authors:  C Gu; Q Li; Y Zhu; Y Qu; G Zhang; M Wang; Y Yang; J Wang; L Jin; Q Wei; D Ye
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-08-04       Impact factor: 5.554

2.  Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans.

Authors:  Daniel C Koboldt; Krishna L Kanchi; Bin Gui; David E Larson; Robert S Fulton; William B Isaacs; Aldi Kraja; Ingrid B Borecki; Li Jia; Richard K Wilson; Elaine R Mardis; Adam S Kibel
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-02       Impact factor: 4.254

3.  Polymorphisms of integrin, alpha 6 contribute to the development and neurologic symptoms of intracerebral hemorrhage in korean population.

Authors:  Hyun-Kyung Park; Dae Jean Jo
Journal:  J Korean Neurosurg Soc       Date:  2011-10-31

4.  Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.

Authors:  Daniel W Lin; Liesel M FitzGerald; Rong Fu; Erika M Kwon; Siqun Lilly Zheng; Suzanne Kolb; Fredrik Wiklund; Pär Stattin; William B Isaacs; Jianfeng Xu; Elaine A Ostrander; Ziding Feng; Henrik Grönberg; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-08-16       Impact factor: 4.254

5.  Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study.

Authors:  Jean-Nicolas Cornu; Sarah Drouin; Géraldine Cancel-Tassin; Pierre Bigot; Abdel-Rahmène Azzouzi; Nicolas Koutlidis; Luc Cormier; Cécile Gaffory; Morgan Rouprêt; Philippe Sèbe; Marc-Olivier Bitker; François Haab; Olivier Cussenot
Journal:  Mol Med       Date:  2011-02-04       Impact factor: 6.354

6.  HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.

Authors:  John S Witte; Joel Mefford; Sarah J Plummer; Jinghua Liu; Iona Cheng; Eric A Klein; Benjamin A Rybicki; Graham Casey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-02-08       Impact factor: 4.254

7.  Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence.

Authors:  Paul J Dluzniewski; Ming-Hsi Wang; Siqun Lilly Zheng; Angelo M De Marzo; Charles G Drake; Helen L Fedor; Alan W Partin; Misop Han; M Daniele Fallin; Jianfeng Xu; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-02       Impact factor: 4.254

Review 8.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

9.  Potential functional variants of KIAA genes are associated with breast cancer risk in a case control study.

Authors:  Jing Zhou; Congcong Chen; Sijun Liu; Wen Zhou; Jiangbo Du; Yue Jiang; Juncheng Dai; Guangfu Jin; Hongxia Ma; Zhibin Hu; Jiaping Chen; Hongbing Shen
Journal:  Ann Transl Med       Date:  2021-04

10.  National Cancer Institute Prostate Cancer Genetics Workshop.

Authors:  William J Catalona; Joan E Bailey-Wilson; Nicola J Camp; Stephen J Chanock; Kathleen A Cooney; Douglas F Easton; Rosalind A Eeles; Liesel M FitzGerald; Matthew L Freedman; Julius Gudmundsson; Rick A Kittles; Elliott H Margulies; Barry B McGuire; Elaine A Ostrander; Timothy R Rebbeck; Janet L Stanford; Stephen N Thibodeau; John S Witte; William B Isaacs
Journal:  Cancer Res       Date:  2011-05-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.